Global E-Health Forum - Hamburg 2010

25-26 October 2010, Hamburg, Germany.
The Global E-Health Forum has been conceived to create a unique opportunity to discuss potential solutions in patient-centric health management. The past three Baltic Conferences on E-Health (2007-2009) have generated considerable interest in countries far beyond the Baltic Sea Region. The reason is simple: Healthcare systems all over the world are facing very similar challenges. Demographic shifts, increased burden of chronic diseases and expensive treatments as well as the impact of globalization - to mention some of the most important ones.

Therefore, organisers of Baltic Conference on E-Health have decided to found the "Global E-Health Forum". The Global E-Health Forum will replace the Baltic Conference on E-Health and is scheduled for following dates:

Global E-Health Forum - Hamburg 2010
25-26 October 2010.

Hosts of Global E-Health Forum 2010 are the European Health Telematics Association (EHTEL), the Hamburg Chamber of Commerce and IBM in cooperation with Asklepios.

Program Outline

  • October 25, 2010
    At the Hamburg Chamber of Commerce, you may expect presentations of keynote speakers from different continents, breakout sessions (workshops and as well as discussion forums) and an accompanying exhibition of solution providers. The first day will end with a reception in the U.S. Consulate General ("the little White House at the lake Alster").
  • October 26, 2010
    The program at Asklepios clinics will offer presentations, guided tours and show cases of solution providers and a panel discussion.

If you are interested in the sponsorship opportunities (platinum sponsor, premium sponsor and sponsor/workshop) or in exhibiting at the Global E-Health Forum on October 25 in the Hamburg Chamber of Commerce, please explore:

Register now to benefit from early bird fee of Euro 299 incl. VAT. Regular fee will be Euro 399 incl. VAT. The fee includes the admission to all conference sessions, lunches, coffee breaks and the evening reception on October 25.

For further information and registration, please visit:
http://www.global-ehealth-forum.com

Most Popular Now

Xenpozyme™ (olipudase alfa-rpcp) approved by FDA a…

The U.S. Food and Drug Administration (FDA) has approved Xenpozyme™ (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid...

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Research reveals widespread use of ineffective COV…

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

Efficacy, cash and more will increase booster shot…

The more effective the COVID-19 booster, the more likely people are to get it, according to new Cornell research. And they are more likely to accept the booster shot with...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...